Question 63

Rabeprazole and aripiprazole

Rabeprazole and aripiprazole are included on the list of look-alike/sound-alike medications maintained by the Institute for Safe Medication Practices (ISMP). This classification is based on their similar spelling and pronunciation, which can lead to potential medication errors.

A) Rabeprazole and aripiprazole

This option is correct as both medications are noted for their visual and phonetic similarities, which can cause confusion among healthcare providers and patients. The ISMP specifically monitors these types of medications to prevent adverse drug events.

B) Prednisolone and risperidone

This option is incorrect because, although both medications are important in their therapeutic areas, they do not share significant visual or phonetic similarities that would warrant inclusion in the ISMP's look-alike/sound-alike list. Their distinct names and uses reduce the risk of confusion.

C) Nicardipine and naloxone

This option is incorrect as well. While they are both important medications, the differences in their names and therapeutic uses make them less likely to be confused with one another. Therefore, they are not listed by the ISMP as look-alike/sound-alike medications.

D) Amlodipine and alprazolam

This option is also incorrect. Though they may share some phonetic elements, the differences in syllable structure and therapeutic classification mean they do not pose a significant risk of confusion. The ISMP does not categorize them as look-alike/sound-alike medications.

Conclusion

Rabeprazole and aripiprazole are recognized by the ISMP as look-alike/sound-alike medications due to their similarities, which can lead to potentially serious medication errors. In contrast, the other options do not present the same level of risk, as their differences help to mitigate confusion in clinical settings. Recognizing and addressing these pairs is crucial for enhancing medication safety.